The use of LThαK (NCT03784885) as an adjuvant for a trivalent inactivated influenza vaccine in phase II clinical trial revealed an acceptable level of safety and higher antigen-specific IgA responses after two nasal vaccinations [95,96]. This evidence concerns the gene CD79A and influenza.